This study is in progress, not accepting new patients
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Santa Monica 5393212, California 5332921 and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- HUYABIO International, LLC.
- ID
- NCT05163028
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 42 study participants
- Last Updated